Co-Founder & Chief Medical Officer at Accomplish Health | Healthcare Futurist | Clinical Assistant Professor of Medicine - OUHSC
Survodutide (GLP1RA/GCGRA) achieves primary endpoint in Ph2 clinical trial. -- Top-line result: ➡ 83% improvement in biopsy-proven MASH❗ https://lnkd.in/gEGRe5vH
🚨 Missed the live Tweetorial by Dr Paolo Tarantino No worries! You can now watch the on-demand video here: https://lnkd.in/dBPp7QHf Join Dr Tarantino as he journeys through a ER+/HER2- #mBC patient case and explores the diagnostic and treatment processes including: 🔸When and how to use molecular testing to tailor treatment strategies 🔸2nd line treatment options for ER+ MBC 🔸The current data on oral SERDs as monotherapy and in combination therapy #MedEd #bcsm
#HappeningNow: In partnership with Incyte, we’re presenting the full results from our AGAVE-201 pivotal trial of axatilimab in patients with chronic GVHD during American Society of Hematology’s #ASH23 Plenary Scientific Session. We believe that the additional positive data from AGAVE-201 further strengthen axatilimab’s strong safety and efficacy profile as a well-differentiated treatment option for patients with refractory chronic GVHD. Read the full press release and view the additional data here: https://bit.ly/3RBczCQ
Complete chronic wound healing as a primary endpoint necessitates trials with large sample sizes and prolonged follow-up to achieve adequate statistical power. Listen to our Head of Clinical Studies, Kieron Day Ph.D., present a novel study metric - Percentage Area Reduction (PAR) - measured over a 4-week period, as a surrogate end point, and how the addition of the geko device significantly increased the PAR rate compared to compression therapy alone in the same cohort in our recently published study. https://lnkd.in/evDXtmyU
Complete chronic wound healing as a primary endpoint necessitates trials with large sample sizes and prolonged follow-up to achieve adequate statistical power. Listen to our Head of Clinical Studies, Kieron Day Ph.D., present a novel study metric - Percentage Area Reduction (PAR) - measured over a 4-week period, as a surrogate end point, and how the addition of the geko device significantly increased the PAR rate compared to compression therapy alone in the same cohort in our recently published study. https://lnkd.in/evDXtmyU
Complete chronic wound healing as a primary endpoint necessitates trials with large sample sizes and prolonged follow-up to achieve adequate statistical power. Listen to our Head of Clinical Studies, Kieron Day Ph.D., present a novel study metric - Percentage Area Reduction (PAR) - measured over a 4-week period, as a surrogate end point, and how the addition of the geko device significantly increased the PAR rate compared to compression therapy alone in the same cohort in our recently published study. https://lnkd.in/evDXtmyU
Can Encorafenib plus binimetinib be used as a new treatment option for #BRAF V600-mutated #thyroidcancer? Scientists perform a multicenter clinical trial to answer this. Check the new study out in #ThyroidJournal. https://ow.ly/e75y50QNPcM
Hot topic alert: At our upcoming conference, William A. Berrigan, MD, RMSK will review current literature on dosing of PRP and its influence on efficacy in knee osteoarthritis. There is significant variability in PRP preparation resulting in heterogeneity in both PRP content and clinical outcomes. Register here to attend this session and more than 30 others: bit.ly/IOF2024
🆕VIDEO: Ex vivo kidney machine perfusion: meta-analysis of randomized clinical trials ➡️https://bit.ly/3UvUZ3D This meta-analysis of machine perfusion included 19 RCTs. The risk of delayed graft function was lowest after hypothermic machine perfusion: relative risk 0.77, 95 per cent confidence interval 0.69 to 0.86). Partial hypothermic perfusion was not effective. 🗨️Soon to be the standard of care? #rct #LeadingSurgicalEducation
Pharmacogenetics & Precision medicine researcher| Education & Development officer| Lecturer
I recently had the privilege of attending an insightful webinar on statins and pharmacogenomics, hosted by ISCP. professor Jasmine Luzum (Talameh), PharmD, PhD, FHFSA, FAHA delivered an informative presentation about the role of pharmacogenomics in identifying high-risk patients who may experience Statin-associated muscle symptoms. The case studies and practical examples shared during the post-presentation discussion greatly enhanced my understanding. These real-world scenarios beautifully illustrated the concepts. I am looking forward to the next webinar #statins #ISCP #pharmacogenomics
A Phase I clinical trial for a BAFF CAR T for relapsed and refractory multiple myeloma is underway. Developed by Reshmi Parameswaran, MD, PhD, and led by Leland Metheny, MD, read how this trial makes significant step in bringing treatment to patients: https://lnkd.in/ej8rmsxm
Healthtech Exec Committed to Patient-First Innovation | Ro Employee #3 | Startup Leader | Strategic Advisor | Builder of High-Performing Teams
6moI think we're going to learn a lot more about glucagon agonism in the coming months and years. Most of us were just taught to think of it as a counter-regulatory hormone to insulin, meaning it mobilizes fuel and raises glucose levels. We are going to learn more about glucagon's effects in partitioning of all macronutrients, its effect on increasing energy expenditure, and its effects on other organs, such as the heart and brain. Too many people think the time we are in is *just* about obesity drugs. I think we are in a time of rapidly increasing our understanding of physiology.